Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors ...
08 Giugno 2021 - 5:45PM
Business Wire
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapies for the treatment
of cancer, today announces that the Japan Patent Office has
officially allowed the patent of Transgene’s oncolytic virus (OV)
backbone VVcopTK-RR- that encodes one or more immune checkpoint
inhibitor(s) (ICIs). This authorization in Japan follows similar
patent grants obtained in several key other geographies including
the US and Europe, providing broad protection of this technology in
the key pharmaceutical markets globally. These patents protect
Transgene’s VVcopTK-RR- backbone encoding one or several ICIs until
2035.
VVcopTK-RR- is a large capacity Vaccinia virus Copenhagen
strain genetically modified with the double deletion TK-RR- which
restricts the viral replication to tumor cells only. This
proprietary backbone is the basis of Transgene’s Invir.IO™
platform. Candidates based on this viral design aim to stimulate an
immune response locally in the tumor and to optimize the safety
profile of the virus.
VVcopTK-RR- PATENTED BACKBONE IS THE BASIS OF TRANSGENE’S
INVIR.IO™ PLATFORM TO DEVELOP MULTIPLE OVs
The new Japanese patent provides further IP by protecting
this proprietary oncolytic virus when it encodes one or more
ICI(s), a type of immunotherapy already approved and used in
several cancer therapies.
Transgene has already obtained patent grants for this new
technology in the US, Europe, Australia, Hong Kong, Israel, and
Russia. In addition, applications are pending in Canada and in
China.
Hedi Ben Brahim, Chairman and CEO of Transgene, said:
“This new patent allowance in Japan is significant for Transgene’s
Invir.IO™ platform as it further highlights our innovation-based
strategy and strengthens the Company’s IP protection in another key
geography. By protecting the vectorization of ICIs in our
VVcopTK-RR- oncolytic viruses, we are extending our Invir.IO™ IP
beyond the original viral backbone protection. As a result, we are
in a position to protect oncolytic viruses coding for ICIs
generated from our Invir.IO™ platform, securing the value of
candidates such as BT-001, which is currently being evaluated in a
Phase I/IIa trial, and several preclinical developments.”
Transgene’s patent portfolio includes approximately 150 granted
patents and 100 pending patent applications as of June 2021.
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses. Transgene has an
ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
www.transgene.fr Follow us on Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210608005867/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Medistrava David Dible/Sylvie Berrebi +44
(0)77 1430 6525 transgene@medistrava.com
Grafico Azioni Transgene (EU:TNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Transgene (EU:TNG)
Storico
Da Apr 2023 a Apr 2024